3B BlackBio Dx Ltd — Board Meeting, 14-08-2025: Board Meeting

The company has approved its financial results for the quarter ended June 30, 2025. Consolidated revenue reached ₹22.23 Cr, with a net profit of ₹12.64 Cr. One-time expenses of ₹0.84 Cr for M&A advisory were noted. The Board also re-appointed Mr. Dhirendra Dubey as Chairman & MD for five years, pending shareholder approval, acknowledging his long-standing leadership. Additionally, Mr. Vivek Saihgal was appointed as an Independent Director, bringing significant industry experience, also pending shareholder approval.